A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
